

Resource Summary Report

Generated by [RRID](#) on Aug 30, 2026

Mono-Mac-1

RRID:CVCL_1425

Type: Cell Line

Proper Citation

RRID:CVCL_1425

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1425

Proper Citation: RRID:CVCL_1425

Description: Cell line Mono-Mac-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Adult acute monocytic leukemia

Defining Citation: [PMID:3162233](#), [PMID:9150350](#), [PMID:11129653](#), [PMID:16142349](#), [PMID:22460905](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#)

Comments: Population: Caucasian., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Mono-Mac-1

Synonyms: MONO-MAC-1, Mono Mac 1, Monomac-1, MONOMAC-1, MonoMac1, MONOMAC1, MM1

Cross References: BTO:BTO_0003928, CLO:CLO_0007827, CLDB:cl3534, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:211, BioSample:SAMN03473331, BioSample:SAMN10988495, cancercellines:CVCL_1425, Cell_Model_Passport:SIDM01022, Cosmic:787458, Cosmic:1089515, DepMap:ACH-001129, DSMZ:ACC-252, DSMZCellDive:ACC-252, EGA:EGAS00001000978, GEO:GSM482510, GEO:GSM887337, GEO:GSM888413, GEO:GSM1670129, IARC_TP53:21702, LiGeA:CCLE_032, LINCS_LDP:LCL-1062,

Lonza:715, PharmacDB:MONOMAC1_959_2019, Progenetix:CVCL_1425, Wikidata:Q54906377

ID: CVCL_1425

Record Creation Time: 20220427T220817+0000

Record Last Update: 20260829T234651+0000

Ratings and Alerts

No rating or validation information has been found for Mono-Mac-1.

No alerts have been found for Mono-Mac-1.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Hong J, et al. (2025) PSPC1 exerts an oncogenic role in AML by regulating a leukemic transcription program in cooperation with PU.1. Cell stem cell, 32(3), 463.

Marova D, et al. (2025) Simvastatin competitively inhibits cellular signaling of lipid-binding antiphospholipid antibodies. Journal of thrombosis and haemostasis : JTH, 23(12), 3883.

Dolton G, et al. (2023) Targeting of multiple tumor-associated antigens by individual T??cell receptors during successful cancer immunotherapy. Cell, 186(16), 3333.

Mill CP, et al. (2022) Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2. Blood, 139(6), 907.

Leick MB, et al. (2022) Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia. Cancer cell, 40(5), 494.

Simeoni F, et al. (2021) Enhancer recruitment of transcription repressors RUNX1 and TLE3 by mis-expressed FOXC1 blocks differentiation in acute myeloid leukemia. Cell reports, 36(12), 109725.

Dufva O, et al. (2020) Immunogenomic Landscape of Hematological Malignancies. Cancer cell, 38(3), 380.

Maes T, et al. (2018) ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia. Cancer cell, 33(3), 495.